The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive
Publications
A Pediatric Case of a D-Penicillamine Induced ANCA-associated Vasculitis Manifesting a Pulmonary-Renal Syndrome.
Journal of Korean medical science. 2019;34(24):e173
D-penicillamine-induced ANA (+) ANCA (+) vasculitis in pediatric patients with Wilson's disease.
Clinical nephrology. 2016;85(5):296-300
ANCA-associated Goodpasture's syndrome in a patient with rheumatoid arthritis on penicillamine.
Indian journal of nephrology. 2012;22(1):45-7
D-Penicillamine-induced ANCA-associated crescentic glomerulonephritis in Wilson disease.
American journal of kidney diseases : the official journal of the National Kidney Foundation. 2007;50(5):821-5
Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies.
Arthritis and rheumatism. 2000;43(2):405-13
Goodpasture-like syndrome associated with anti-myeloperoxidase antibodies following penicillamine treatment.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 1995;10(10):1925-8